open-burger-menu
Search Icon
Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research
📈 NEW Report: Abortions, Tax Funding UP at Planned Parenthood >>
Search Icon
Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

close-panel
Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Research Type:

Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research

Sort 1464 results by:

Filter results further
Filter Applied. Clear All

Latest Posts

October 6, 2026 A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Inside The Government Decision That Opened Up Abortion Pill Floodgates Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone
Research Type
Publication Type
By State
See All
By Author
See All
Reset All Filters

Did You Know ?

Did You Know ?

In the fourth week, the embryonic heart starts beating. The neural tube, which becomes the brain and spinal cord, forms. At this point, a woman has likely only been aware of her pregnancy for one week.

Did You Know ?

In the seventh week after conception, networks of neurons produce brain waves that have been recorded as early as 6 ½ weeks after conception. The embryo spontaneously moves his arms, hands, and legs, and may even hiccup. The embryo’s heart now has all four chambers.

Did You Know ?

By the seventeenth and eighteenth week after gestation, the fetus shows a clear response to pain in multiple studies, and at least one brain pathway is mature enough to create a perception of pain. The fetus also practices breathing, crying, and breastfeeding in the womb. The fetal heart has beat over 20 million times and circulates about 55 quarts of blood per day.

Did You Know ?

In the eighth month of pregnancy the fetal brain is ready to learn! At 32 weeks after conception, neurons are creating 40,000 new connections, called synapses, every second! With repeated exposures, the fetus can learn flavors, nursery rhymes, songs, and even words that she will recognize after birth!

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review
Latest Research / Life & the Law

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

This paper critically analyzes the FDA's 2021 REMS Review leading to the removal of the in-person dispensing requirement for mifepristone.

Zachary Sluzala,… Ingrid Skop,…
October 6, 2026
Inside The Government Decision That Opened Up Abortion Pill Floodgates
Latest Research / Abortion Drugs

Inside The Government Decision That Opened Up Abortion Pill Floodgates

The decision "fell well short" of the FDA's standards.

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone
Latest Research / Life & the Law

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

This paper critically analyzes the FDA's 2021 literature review that served as the basis for its controversial decision to remove…

Ingrid Skop,…
October 6, 2026
Peer-Reviewed Article: FDA Lacked Evidence to Drop In-Person Abortion Drug Requirement
Latest Research / General

Peer-Reviewed Article: FDA Lacked Evidence to Drop In-Person Abortion Drug Requirement

A new peer-reviewed article on the Food and Drug Administration’s (FDA) 2021 complete review of mifepristone’s Risk Evaluation and Mitigation…

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
Abortion Reporting: Kentucky (2025)
Latest Research / Maternal & Public Health

Abortion Reporting: Kentucky (2025)

In 2025, five brick-and-mortar abortions were reported in Kentucky by the state’s Cabinet for Health and Family Services. The data…

Elyse Gaitan Mia Steupert,…
October 5, 2026
Maternal & Public Health

Abortion Reporting: Illinois (2022)

Abortions in Illinois increased in 2022 by 9% from 2021, with a total of 56,457 in 2022 and 51,797 in 2021.

Mia Steupert, M.A. Tessa Cox
February 29, 2024
Maternal & Public Health

Abortion Reporting: Wisconsin (2022)

Wisconsin’s 2022 abortion report was released in January 2024, showing that abortions decreased significantly from 2021.

Mia Steupert, M.A. Tessa Cox
February 29, 2024
Maternal & Public Health

Abortion Reporting: Oregon (2022)

A total of 8,672 abortions were reported in Oregon in 2022, an increase of 22% from 2021.

Mia Steupert, M.A. Tessa Cox
February 29, 2024
Maternal & Public Health

CLI Authors’ Responses to Sage Concerns and Retractions

On February 5, 2024, Sage Publications retracted three peer-reviewed articles authored by affiliates of the Charlotte Lozier Institute. Prior to these retractions, Sage issued an expression of concern against the first of the three articles in July of 2023. Reproduced here are the authors’ initial response to Sage’s notice informing CLI of its intention to issue an expression of concern, as well as the authors’ subsequent response to the official retractions.

charlotte-lozier-institute Charlotte Lozier Institute
February 21, 2024
Lozier Institute Amicus Brief in Support of Ecuador Law Limiting Abortion
Life & the Law

Lozier Institute Amicus Brief in Support of Ecuador Law Limiting Abortion

On February 19, 2024, CLI associate scholar Mary E. Harned, J.D., submitted an amicus brief on behalf of CLI to the Constitutional Court of Ecuador. This brief was written in support of three provisions of Ecuador’s Organic Law Regulating the Voluntary Interruption of Pregnancy: (1) a requirement that ultrasounds be performed prior to abortion decisions, (2) a 12-week gestational age limit on abortion, and (3) a prohibition on the commodification of post-abortion fetal remains. Following is CLI’s amicus brief reproduced in full.

charlotte-lozier-institute Charlotte Lozier Institute
February 21, 2024
Life & the Law

Public Comment: Lozier Institute on CDC’s Notice of Proposed Modifications to Assisted Reproductive Technology Program Reporting

On January 25, 2024, CLI submitted a public comment to the CDC regarding newly proposed modifications related to data collection and reporting from assisted reproductive technology programs and modifications to data validation procedures. In light of the fact that none of these proposed changes recognized the inherent value and dignity of nascent human beings created from ART programs, including IVF, CLI took the opportunity to encourage the CDC to do so and to consider limiting, reporting, or regulating "the number of living embryos destined for research and destruction."

charlotte-lozier-institute Charlotte Lozier Institute
February 21, 2024
CLI Scholars React to Nature Medicine Study
Abortion Drugs

CLI Scholars React to Nature Medicine Study

Following the release of a study in Nature Medicine, which discussed the “safety and effectiveness” of abortion drugs acquired through telehealth, Tessa Longbons Cox, senior research associate at the Charlotte Lozier Institute, made the following statement:

charlotte-lozier-institute Charlotte Lozier Institute
February 16, 2024
Maternal & Public Health

Five Facts About “Life-Limiting” Fetal Conditions

Babies prenatally diagnosed with a life-limiting condition often face discrimination. Some continue to refer to these conditions as “lethal” or “fatal” or “incompatible with life.” In such cases abortion is often offered as the only option to families. The fact is, however, that some of these babies may require very minimal medical support after birth or may benefit and be stabilized for further evaluation with medical interventions routinely performed on babies without lethal labels.

charlotte-lozier-institute Charlotte Lozier Institute
February 15, 2024

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image